A Randomized, Double-Blind, Placebo-controlled, Multi-Center, Phase 2 Clinical Trial to Evaluate the Efficacy and the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation (EP) in HPV type 16 and/or 18 Positive Patients with Biopsy-proven Cervical Intraepithelial Neoplasia Grade 2 (CIN 2), Grade 2/3 (CIN 2/3) or Grade 3 (CIN3)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Jul 2017
At a glance
- Drugs GX 188E (Primary)
- Indications Cervical intraepithelial neoplasia
- Focus Therapeutic Use
- Sponsors Genexine
- 11 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Mar 2018.
- 11 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 31 May 2017 This trial has been completed in Estonia, according to European Clinical Trials Database